These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. In vitro hemolysis: guidance for the pharmaceutical scientist. Amin K; Dannenfelser RM J Pharm Sci; 2006 Jun; 95(6):1173-6. PubMed ID: 16639718 [TBL] [Abstract][Full Text] [Related]
46. Amorphous solid dispersion successfully improved oral exposure of ADX71943 in support of toxicology studies. Ayad MH; Bonnet B; Quinton J; Leigh M; Poli SM Drug Dev Ind Pharm; 2013 Sep; 39(9):1300-5. PubMed ID: 23066824 [TBL] [Abstract][Full Text] [Related]
47. Nasal absorption of propranolol from different dosage forms by rats and dogs. Hussain A; Hirai S; Bawarshi R J Pharm Sci; 1980 Dec; 69(12):1411-3. PubMed ID: 7463327 [TBL] [Abstract][Full Text] [Related]
48. [Stability and stabilization of drugs. V. Drug forms]. Speiser P Pharm Acta Helv; 1968; 43(2):65-78. PubMed ID: 5720916 [No Abstract] [Full Text] [Related]
49. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Bittner B; Mountfield RJ Curr Opin Drug Discov Devel; 2002 Jan; 5(1):59-71. PubMed ID: 11865674 [TBL] [Abstract][Full Text] [Related]
50. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions. Serajuddin AT; Sheen PC; Mufson D; Bernstein DF; Augustine MA J Pharm Sci; 1988 Apr; 77(4):325-9. PubMed ID: 3379591 [TBL] [Abstract][Full Text] [Related]
51. Design of fenofibrate microemulsion for improved bioavailability. Hu L; Wu H; Niu F; Yan C; Yang X; Jia Y Int J Pharm; 2011 Nov; 420(2):251-5. PubMed ID: 21907776 [TBL] [Abstract][Full Text] [Related]
52. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation. McIntosh MP; Schwarting N; Rajewski RA J Pharm Sci; 2004 Oct; 93(10):2585-94. PubMed ID: 15349968 [TBL] [Abstract][Full Text] [Related]
53. Biological and chemical evaluation of a 43-year-old sample of Cannabis fluidextract. Kubena RK; Barry H; Segelman AB; Theiner M; Farnsworth NR J Pharm Sci; 1972 Jan; 61(1):144-5. PubMed ID: 5058639 [No Abstract] [Full Text] [Related]
54. Development and bioavailability assessment of ramipril nanoemulsion formulation. Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045 [TBL] [Abstract][Full Text] [Related]
55. Sulfolane-induced convulsions in rodents. Andersen ME; Jones RA; Kurlansik L; Mehl RG; Jenkins LJ Res Commun Chem Pathol Pharmacol; 1976 Nov; 15(3):571-80. PubMed ID: 825938 [TBL] [Abstract][Full Text] [Related]
57. Partitioning phenomena in dosage form and biopharmaceutical design. II. Some partitioning considerations in dosage form design. Schumacher GE Am J Hosp Pharm; 1971 Dec; 28(12):985-8. PubMed ID: 5135196 [No Abstract] [Full Text] [Related]
58. The pharmacologic profile of nabilone: a new antiemetic agent. Stark P Cancer Treat Rev; 1982 Dec; 9 Suppl B():11-6. PubMed ID: 6299549 [No Abstract] [Full Text] [Related]
59. A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats. Chen H; Shi S; Zhao M; Zhang L; He H; Tang X Drug Dev Ind Pharm; 2010 Dec; 36(12):1444-53. PubMed ID: 21050136 [TBL] [Abstract][Full Text] [Related]
60. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. Piao HM; Balakrishnan P; Cho HJ; Kim H; Kim YS; Chung SJ; Shim CK; Kim DD Int J Pharm; 2010 Aug; 395(1-2):309-16. PubMed ID: 20635476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]